Scailyte AG Company

A new and emerging type of analytical devices produce rich data-sets by measuring hundreds of parameters from millions of individual cells. The resulting single-cell data holds the information needed for early disease detection, but it requires sophisticated and innovative computational approaches in order to extract the relevant information.

Scailyte AG addresses this problem by developing artificial intelligence (AI) software for single-cell data analysis. The underlying algorithms allow them to associate patterns in single-cell data with disease status, similar to how state-of-the-art methods for object recognition associate pixel patterns with objects. They provide a software solution (ScaiVision), wrapping the AI technology for R&D customers from academia, pharmaceutical and clinics.

Additionally, through their ScaiBioMarker Discovery service, by partnering with pharmaceutical & biotechnology companies they provide special single-cell technology and expertise for novel biomarker discovery, which will yield ultra-sensitive biomarkers for early and precise detection of a wide range of complex diseases.
Technology: Precision Medicine
Industry: P3 Medicine
Headquarters: Sursee, Luzern, Switzerland
Founded Date: 2017
Employees Number: 1-10
Funding Status: Seed

Visit Website
Register and Claim Ownership